MARKET

STRO

STRO

Sutro Biopharma
NASDAQ
0.9324
+0.1223
+15.10%
After Hours: 0.9400 +0.0076 +0.82% 19:59 03/17 EDT
OPEN
0.8171
PREV CLOSE
0.8101
HIGH
0.9700
LOW
0.7621
VOLUME
7.13M
TURNOVER
--
52 WEEK HIGH
6.13
52 WEEK LOW
0.7621
MARKET CAP
78.11M
P/E (TTM)
-0.3149
1D
5D
1M
3M
1Y
5Y
1D
U.S. RESEARCH ROUNDUP- Array Technologies, Nextracker, Sutro Biopharma
Reuters · 20h ago
Reported Saturday, Sutro Highlights Late-Breaking Refrαme-O1 Data Demonstrating 32% ORR And 96% DCR With Optimized Luvelta Dosing In PROC Patients
Benzinga · 20h ago
Sutro Biopharma :REFRaME-O1 Trial Data On Luvelta Shows Promise In Platinum-Resistant Ovarian Cancer
NASDAQ · 1d ago
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
Barchart · 2d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 3d ago
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
Benzinga · 3d ago
Dow Jumps Over 600 Points; US Consumer Sentiment Tumbles In March
Benzinga · 3d ago
Sutro Biopharma Cut to Market Perform From Market Outperform by Citizens Capital Markets
Dow Jones · 3d ago
More
About STRO
More
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Recently
Symbol
Price
%Change

Webull offers Sutro Biopharma Inc stock information, including NASDAQ: STRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STRO stock methods without spending real money on the virtual paper trading platform.